The IGF pathway is activated in insulinomas but downregulated in metastatic disease

Mieke E. R. Henfling, Aurel A. Perren, Anja M. Schmitt, Christiane M. Saddig, Achim A. Starke, Robert G. Riedl, Yvonne M. H. Versleijen-Jonkers, Diana M. Sprij-Mooij, Frans C. S. Ramaekers, Leo J. Hofland, Ernst-Jan M. Speel*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1005-1018
Number of pages14
JournalEndocrine-Related Cancer
Volume25
Issue number12
DOIs
Publication statusPublished - Dec 2018

Keywords

  • insulinoma
  • pancreatic neuroendocrine tumor (PanNET)
  • EGFR
  • IGF2
  • IGF1R
  • mTOR signaling
  • metastatic disease
  • GROWTH-FACTOR RECEPTOR
  • ENDOCRINE PANCREATIC TUMORS
  • NEUROENDOCRINE TUMORS
  • MTOR PATHWAY
  • FACTOR SYSTEM
  • EXPRESSION
  • SURVIVAL
  • ANTAGONISTS
  • EVEROLIMUS
  • PATTERNS

Cite this